PRCT
PROCEPT BioRobotics Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow -7.6% ·
net new positions -10.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 94 | +5 | 33.31M | $752.45M | +11 | −5 |
| Q1 2026 | 91 | -1 | 33.28M | $833.46M | +12 | −14 |
| Q4 2025 | 93 | +1 | 39.36M | $1.24B | +3 | −1 |
| Q3 2025 | 16 | -3 | 25.33M | $904.19M | — | −3 |
| Q2 2025 | 16 | 0 | 23.48M | $1.35B | +1 | −1 |
| Q1 2025 | 13 | +2 | 6.67M | $388.41M | +2 | — |
| Q4 2024 | 11 | 0 | 6.19M | $498.09M | +1 | −1 |
| Q3 2024 | 10 | -1 | 3.73M | $299.03M | — | −1 |
| Q2 2024 | 11 | — | 4.04M | $246.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.11M | +8.2% | $88.68M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.11M | +8.2% | $88.68M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.07M | -4.0% | $86.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.07M | -4.0% | $86.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.07M | -4.0% | $86.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.07M | -4.0% | $86.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 777.43K | -33.5% | $62.29M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 777.43K | -33.5% | $62.29M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 463.38K | +67.2% | $37.13M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 185.21K | -30.1% | $14.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Millennium Management ✦ | 54.61K | -41.1% | $4.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 43.62K | +59.2% | $3.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 15.15K | +63.2% | $1.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 9.02K | +75.4% | $722,362 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 9.02K | +75.4% | $722,362 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 2.84K | -57.8% | $227,781 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $2.81M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 254 holders, 55.53M shares, $1.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · President, CEO · 23.90K sh @ 20.85 · $498,315
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology